Bright Minds Biosciences launches a Phase 2 trial for BMB-101, targeting drug-resistant epilepsy with high unmet needs.
The company trades at a $5M market cap,...
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies.
NurExone chose to base its...
CULT Food Science Corp. ("CULT" or the "Company") (CSE: CULT) (OTC: CULTF) (FRA: LN0) is a disruptive food technology platform pioneering the commercialization of lab-grown meat and...
Always neat to introduce timely juniors with great potential. In this case, our constituents are OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"),...
Successfully raised $6.4 million in IPO, securing operations through mid-2025.
Prioritizing fast-tracked development of OST-HER2, a promising treatment for HER-2 positive osteosarcoma.
Positioned to capitalize on...